Role of mitogen-activated protein kinase kinase 4 in cancer

被引:124
作者
Whitmarsh, A. J.
Davis, R. J.
机构
[1] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA
[2] Univ Massachusetts, Fac Life Sci, Worcester, MA 01605 USA
关键词
MAP kinase; MKK4; JNK; p38; tumor suppressor;
D O I
10.1038/sj.onc.1210410
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitogen-activated protein (MAP) kinase kinase 4 (MKK4) is a component of stress activated MAP kinase signaling modules. It directly phosphorylates and activates the c-Jun N-terminal kinase (JNK) and p38 families of MAP kinases in response to environmental stress, proinflammatory cytokines and developmental cues. MKK4 is ubiquitously expressed and the targeted deletion of the Mkk4 gene in mice results in early embryonic lethality. Further studies in mice have indicated a role for MKK4 in liver formation, the immune system and cardiac hypertrophy. In humans, it is reported that loss of function mutations in the MKK4 gene are found in approximately 5% of tumors from a variety of tissues, suggesting it may have a tumor suppression function. Further more, MKK4 has been identified as a suppressor of metastasis of prostate and ovarian cancers. However, the role of MKK4 in cancer development appears complex as other studies support a pro-oncogenic role for MKK4 and JNK. Here we review the biochemical and functional properties of MKK4 and discuss the likely mechanisms by which it may regulate the steps leading to the formation of cancers.
引用
收藏
页码:3172 / 3184
页数:13
相关论文
共 132 条
[1]   Hyperphosphorylation of the retinoid X receptor α by activated c-Jun NH2-terminal kinases [J].
Adam-Stitah, S ;
Penna, L ;
Chambon, P ;
Rochette-Egly, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :18932-18941
[2]   Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation [J].
Alt, JR ;
Cleveland, JL ;
Hannink, M ;
Diehl, JA .
GENES & DEVELOPMENT, 2000, 14 (24) :3102-3114
[3]   The promise of retinoids to fight against cancer [J].
Altucci, L ;
Gronemeyer, H .
NATURE REVIEWS CANCER, 2001, 1 (03) :181-193
[4]   Pathways governing G1/S transition and their response to DNA damage [J].
Bartek, J ;
Lukas, J .
FEBS LETTERS, 2001, 490 (03) :117-122
[5]   Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation [J].
Behrens, A ;
Jochum, W ;
Sibilia, M ;
Wagner, EF .
ONCOGENE, 2000, 19 (22) :2657-2663
[6]   TGFβ:: the molecular Jekyll and Hyde of cancer [J].
Bierie, Brian ;
Moses, Harold L. .
NATURE REVIEWS CANCER, 2006, 6 (07) :506-520
[7]  
Bost F, 1999, MOL CELL BIOL, V19, P1938
[8]   The defective transforming phenotype of c-Jun Ala63/73 is rescued by mutation of the C-terminal phosphorylation site [J].
Bost, F ;
Caron, L ;
Vial, E ;
Montreau, N ;
Marchetti, I ;
Dejong, V ;
Defize, L ;
Castellazzi, M ;
Binétruy, B .
ONCOGENE, 2001, 20 (50) :7425-7429
[9]   Mechanism of p38 MAP kinase activation in vivo [J].
Brancho, D ;
Tanaka, N ;
Jaeschke, A ;
Ventura, JJ ;
Kelkar, N ;
Tanaka, Y ;
Kyuuma, M ;
Takeshita, T ;
Flavell, RA ;
Davis, RJ .
GENES & DEVELOPMENT, 2003, 17 (16) :1969-1978
[10]   p38 MAP kinase's emerging role as a tumor suppressor [J].
Bulavin, DV ;
Fornace, AJ .
ADVANCES IN CANCER RESEARCH, VOL 92, 2004, 92 :95-118